Tang Liang, Oh Yong-Seog, Li Hongmei, Song Juan, Chen Peng-Sheng, Lin Shien-Fong
Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center and David Geffen School of Medicine, UCLA, Los Angeles, California 90048, USA.
Heart Rhythm. 2007 Sep;4(9):1208-13. doi: 10.1016/j.hrthm.2007.05.031. Epub 2007 Jun 8.
Upregulation of plasma nerve growth factor (NGF) is indicative of cardiac nerve sprouting that is underlying the mechanisms for cardiac arrhythmias. A conventional assay method (e.g., enzyme-linked immunosorbent assay [ELISA]) is usually time consuming and technically complicated for NGF analysis for potential arrhythmia prognosis.
This study is to develop a rapid and and reliable assay method for point-of-care (POC) testing of plasma NGF.
We recently developed a fiberoptic immunobiosensor for point-of-care testing of human plasma NGF. Physiological concentrations of NGF (1 to 200 ng/ml) could be quantified in both buffer and human blood plasma samples (100 microl) within 5 min. The intra-assay coefficient of variation was 5%, and the interassay coefficient of variation was 8%. The clinical utility of the NGF biosensor was evaluated using clinical blood samples from atrial fibrillation patients (n = 21). Peripheral venous blood was sampled before and immediately after radiofrequency ablation and again at postoperative day 1.
The NGF level did not change significantly between before (15.73 +/- 16.67 ng/ml) and immediately after radiofrequency ablation (13.58 +/- 11.45 ng/ml, P = NS); however, there was a significant elevation to 28.41 +/- 19.52 ng/ml in postoperative day 1 (P <.01). In a follow-up study (11 +/- 1 months), the increased magnitude in patients with atrial fibrillation recurrence (4.1-fold +/- 1.96-fold) was significantly higher than those without (1.72-fold +/- 0.53-fold; P <.001). The results were highly comparable to those of the ELISA analysis.
Because of the comparable data accuracy and much faster assay time as compared with ELISA, the fiberoptic biosensor is promising as a clinical POC assay method for plasma NGF analysis at patient bedsides for potential cardiac disease diagnosis and prognosis.
血浆神经生长因子（NGF）上调表明心脏神经发芽，这是心律失常机制的基础。传统的检测方法（如酶联免疫吸附测定法[ELISA]）通常耗时且技术复杂，难以用于分析NGF以预测潜在的心律失常。
本研究旨在开发一种快速、可靠的血浆NGF即时检测（POC）方法。
我们最近开发了一种用于人血浆NGF即时检测的光纤免疫生物传感器。在5分钟内可对缓冲液和人血浆样本（100微升）中的生理浓度NGF（1至200纳克/毫升）进行定量。批内变异系数为5%，批间变异系数为8%。使用心房颤动患者（n = 21）的临床血样评估NGF生物传感器的临床实用性。在射频消融术前和术后立即采集外周静脉血，并在术后第1天再次采集。
射频消融术前（15.73±16.67纳克/毫升）和术后立即（13.58±11.45纳克/毫升，P =无统计学意义）NGF水平无显著变化；然而，术后第1天显著升高至28.41±19.52纳克/毫升（P <.01）。在一项随访研究（11±1个月）中，心房颤动复发患者的升高幅度（4.1倍±1.96倍）显著高于未复发患者（1.72倍±0.53倍；P <.001）。结果与ELISA分析高度可比。
由于与ELISA相比数据准确性相当且检测时间快得多，光纤生物传感器有望作为一种临床POC检测方法，用于在患者床边分析血浆NGF，以进行潜在心脏病的诊断和预后评估。
